IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Boosted by Teacher Retirement System of Texas

Teacher Retirement System of Texas lifted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 201.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,432 shares of the medical research company's stock after purchasing an additional 21,679 shares during the period. Teacher Retirement System of Texas' holdings in IQVIA were worth $5,718,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IQV. Norges Bank acquired a new position in IQVIA during the fourth quarter worth about $336,041,000. American Century Companies Inc. raised its position in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after acquiring an additional 905,960 shares during the last quarter. Invesco Ltd. raised its position in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares during the last quarter. Canada Pension Plan Investment Board raised its position in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in IQVIA by 211.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock worth $189,691,000 after acquiring an additional 655,153 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. Barclays cut their price objective on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Mizuho lowered their target price on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Finally, UBS Group lowered their target price on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Down 1.0%

IQV traded down $1.67 during trading on Monday, hitting $162.57. The company had a trading volume of 1,489,122 shares, compared to its average volume of 1,652,666. The company has a market cap of $28.12 billion, a PE ratio of 22.15, a P/E/G ratio of 1.82 and a beta of 1.30. The business has a 50-day moving average of $150.86 and a 200-day moving average of $173.03. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.54 earnings per share. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.